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Abstract 
Background: Hyperhomocysteinemia is a risk factor for neurodegeneration, and binding of 
copper by homocysteine is a putative underlying mechanism. As mutations of the copper-
dependent superoxide dismutase are observed in familial ALS, we tested whether genetic 
variants with influence on homocysteine metabolism are associated with ALS.  
Subjects and Methods: We compared the frequency of seven variants of genes involved in 
homocysteine metabolism in 162 patients with sporadic ALS and 162 controls who did not 
significantly differ in age (t=1.27; p=0.205) and gender (Chi=2.48; p=0.115) using binary 
regression analysis.  
Results: The variant MTHFR c.677C>T was significantly associated with ALS, i.e., the T-
allele was more frequent among patients. Explorative regression analysis revealed that 
MTHFR c.677C>T was not associated with spinal ALS, but with bulbar onset: CC/CT/TT in 
patients 0.33/0.51/0.16 versus 0.50/0.44/0.06 in controls; Wald=5.73; p=0.017. In addition, 
DHFR c.594+59del19bp was not associated with spinal, but with bulbar onset: 
del,del/del,ins/ins,ins in patients 0.16/0.67/0.18 versus 0.11/0.52/0.37 in controls; Wald=5.02; 
p=0.025. The other variants did not show significant associations.  
Discussion: The variants MTHFR c.677C>T and DHFR c.594+59del19bp are involved in 
homocysteine metabolism. Homocysteine is neurotoxic and binds copper. Thus, the 
individual variability of homocysteine metabolism, e.g. due to genetic variants, may 
contribute to the vulnerability of ALS.  
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Introduction 
Amyotrophic lateral sclerosis (ALS) is characterized by progressive degeneration of upper 
and lower motor neurons in motor cortex, brainstem and spinal cord leading to progressive 
limb weakness, bulbar palsy and respiratory insufficiency. Spinal onset is observed in the 
majority of cases, but bulbar onset is seen in up to 30%. In later disease stages almost all 
patients demonstrate bulbar involvement. The mean survival time is 3-5 years. Respiratory 
failure is the major life-limiting factor (1-3). Most cases are sporadic (sALS), but about 10% 
are familial (fALS). About 15-20% of autosomal dominant fALS patients show mutations in 
the copper-dependent superoxide dismutase gene (SOD1) (4,5). Our previous finding of 
hyperhomocysteinemia leading to copper binding, deficiency of cytochrome oxidase C and 
consequently apoptosis in different cell lines including primary rat neurons prompted us to 
test whether variants of genes involved in homocysteine metabolism are associated with the 
development of ALS (6,7). We analysed the frequency of seven genetic variants of 
homocysteine metabolism in a case-control-study. Further, explorative analyses were 
performed to investigate whether these variants are associated with the clinical presentation 
of ALS. 
 
Subjects and Methods 
Serial Caucasian adult patients with sporadic ALS were recruited at the Departments of 
Neurology of the University Hospitals of Ulm, Germany, and Zurich, Switzerland. Patients 
were diagnosed to have definite or probable sporadic ALS by modified Airlie House El 
Escorial criteria (8). In brief, diagnosis was based on clinical examination, electromyography 
and nerve conduction studies. Cranial and cervical magnetic resonance imaging were 
performed when considered necessary. Electromyography (EMG) showed signs of anterior 
horn cell degeneration whereas nerve conduction studies were without signs of other 
underlying neurological disorders. All patients underwent routine biochemical tests including 
thyroid hormones, serum protein electrophoresis, complete blood count and standard CSF 
analysis. Healthy age- and gender-matched Caucasian subjects, e.g., partner of patients 
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without any history of neurological disease, served as controls. DNA sampling and genetic 
analyses were approved by the local Ethics Committees. Written informed consent for 
genetic analysis was obtained from each individual.  
In total, 162 patients and 162 controls were enrolled (table 1). Patients and controls did not 
significantly differ in age (t = 1.27; p = 0.205) or gender (Chi = 2.48; p=0.115).  
Genomic DNA was prepared from peripheral leukocytes and was used for genotyping of 
seven variants of genes involved in homocysteine metabolism by allele specific PCR 
amplification or by PCR amplification with subsequent restriction analysis (9): 
- cystathionine beta-synthase (CBS) c.844_855ins68 (splice alteration affecting the 
transcript level; GenBank S78267.1) 
- dihydrofolate reductase (DHFR) c.594+59del19bp (intronic deletion supposedly 
affecting the transcript level; GenBank NM_000791.3) 
- MTHFR c.677C>T (missense mutation p.A222V; rs1801133) 
- MTHFR c.1298A>C (missense mutation p.E429A; rs1801131) 
- methionine-homocysteine S-methyltransferase (MTR; “methionine synthase”) 
c.2756A>G (missense mutation p.D919G; rs1805087) 
- reduced folate carrier 1 (RFC1) c.80G>A (missense mutation p.R27H; rs1051266) 
- transcobalamin 2 (Tc2) c.776C>G (missense mutation p.P259R; rs1801198) 
Genotyping was successful for all DNA samples. A chi2 goodness-of-fit analysis was 
performed to analyse whether the distribution of genotypes was in disequilibrium with the 
Hardy-Weinberg-equation in the controls. Due to a Hardy-Weinberg disequilibrium in the 
controls (p<0.001), the variant RFC1 c.80G>A was excluded from further analyses. Age and 
gender were compared between groups by an independent t-test or Pearson’s chi2-test. To 
analyse independent associations between genetic variants and clinical parameters and to 
avoid artifacts due to multiple testing or due to any heterogeneity concerning age and gender 
between patients and controls, we used multivariate analyses, i.e., binary regression with all 
genotypes, age and gender as covariables and diagnosis “ALS” versus “control” as 
dependent variable to analyse associations of genotypes with the incidence of ALS as 
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primary parameter of interest. Exploratively, the genotypes together with age and gender as 
covariables were analysed with age of onset or, alternatively, disease duration as dependent 
variable in linear regression analysis. In addition, binominal regression analysis with all 
genotypes, age and gender as covariables was used to analyse the association of genotypes 
with subtypes of the clinical presentation defined by bulbar versus spinal disease onset. 
Finally, explorative analyses investigated subgroups defined by age and gender.  
 
Results 
The results of the multivariate binominal regression analysis of the genetic variants with age 
and gender as covariables are shown in table 2.  
The variant MTHFR c.677C>T was significantly associated with ALS, i.e., the T-allele was 
more frequent in patients than in controls with 6% carriers of the T-allele in homozygous 
state in the controls compared with 13% in the patients (Wald=5.39; p=0.020). The other 
genetic variants did not show such associations. Explorative analyses did not reveal further 
significances when subgroups were analyzed defined by gender or age. None of the genetic 
variants was associated with age of onset or disease duration. However, explorative binary 
regression analysis showed that MTHFR c.677C>T was not significantly associated with ALS 
with spinal onset of disease (CC/CT/TT in patients: 0.43/0.45/0.12, and 0.50/0.44/0.06 in 
controls; Wald = 3.14; p = 0.076), but with bulbar onset (CC/CT/TT in patients: 
0.33/0.51/0.16, and 0.50/0.44/0.06 in controls; Wald = 5.73; p=0.017). In addition, DHFR 
c.594+59del19bp was not associated with spinal onset ALS (del,del/del,ins/ins,ins in 
patients: 0.14/0.46/0.40, and 0.11/0.52/0.37 in controls; Wald = 0.141; p = 0.707), but with 
bulbar onset ALS (del,del/del,ins/ins,ins in patients: 0.16/0.67/0.18, and 0.11/0.52/0.37 in 
controls; Wald = 5.02; p=0.025).  
 
Discussion 
In our study sample, the MTHFR variant c.677C>T was associated with sporadic ALS and 
thus may be a risk factor for the development of this disease. If subgroups were analyzed, 
this association was only significant for bulbar onset ALS, but not for spinal ALS. The 
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thermolabile MTHFR variant, caused by the T-allele of MTHFR c.677C>T, reduces MTHFR 
activity yielding elevated homocysteine plasma levels (10). Elevated homocysteine plasma 
levels are a risk factor for neurodegeneration. Binding of copper by homocysteine and an 
impairment of copper-dependent enzymes like cytochrome C oxidase and superoxide 
dismutase 1 (SOD1), which play a role in familial ALS, may be underlying mechanisms (6). 
Thus, on a genetic basis, homocysteine metabolism, speculatively via its influence on copper 
homeostasis, may contribute to ALS pathogenesis. However, we cannot estimate to what 
extent our data depend on our study population. Due to the limitations of any association 
study, these results must be re-tested in independent study samples, especially since the 
frequency of the TT genotype of MTHFR c.677C>T in the control group was lower than 
expected (11-13). Also, the association of MTHFR c.677C>T with bulbar ALS only, which 
was observed in secondary explorative subgroup analyses, and the association of DHFR 
c.594+59del19bp with bulbar ALS should be re-tested. The lack of association of the genetic 
variants with the clinical course argues against a major influence of homocysteine 
metabolism on ALS outcome. However, in the absence of a curative therapy approach yet, a 
confirmed association of elevated homocysteine plasma levels with ALS development may 
lead to novel prophylactic or therapeutic strategies, as reduction of homocysteine plasma 
levels can be easily accomplished (7). 
 
Disclosure: All authors report no conflicts of interest. 
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Table 1. Demographic data. Disease duration means time from disease onset until death or 
tracheotomy. 14 patients from Ulm who were still alive at genetic analysis were excluded 
from analyses. Data for enrolment, gender distribution and type of onset are given as 
percent. Data for age and disease duration are given as mean ± standard deviation (SD). 
 patients (n=162) controls (n=162) 
enrolled in Ulm / Zurich 0.73 / 0.23 0.72 / 0.24 
female / male gender 0.33 / 0.67 0.39 / 0.61 
spinal / bulbar onset  0.67 / 0.33 -- 
age (patients: at onset) in years ± 1 sd 
(range)1 
60±12 (24-92) 59±15 (18-88) 
disease duration in months ± 1 sd (range) 50.7 ± 39.3 (6-332) -- 
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Table 2: Association of genetic variants of homocysteine metabolism with ALS. 
Variant Genotype Wald; p 
CBS c.844_845ins68bp del/del del/ins ins/ins  
patients  0.87 0.11 0.01 
controls  0.81 0.19 0 
0.47; 0.495 
DHFR c.594+59del19bp del/del del/ins ins/ins  
patients  0.14 0.52 0.33 
controls  0.11 0.52 0.37 
0.80; 0.372 
MTHFR c.677C>T CC CT TT  
patients  0.40 0.48 0.13 
controls  0.50 0.44 0.06 
5.39; 0.020 
MTHFR c.1298A>C AA AC CC  
patients  0.49 0.41 0.10 
controls  0.48 0.41 0.11 
0.19; 0.546 
MTR c.2756A>G AA AG GG  
patients  0.69 0.30 0.01 
controls  0.67 0.29 0.04 
0.39; 0.530 
TC2 c.677C>G CC CG GG  
patients  0.33 0.46 0.21 
controls  0.30 0.44 0.26 
0.21; 0.646 
 
